Fresenius Kabi is responding to the significant increase in worldwide demand for essential drugs for the treatment of COVID-19 patients, especially medicines used for sedation such as Propofol and pain management drugs. The company is maximizing supply with all compatible manufacturing capacity now dedicated to these vital drugs. Fresenius Kabi has made significant, future-oriented investments in recent years into both automation and capacity in its manufacturing facilities; these are now enabling treatment for more patients worldwide. Moreover, the company commits itself to keeping prices for essential drugs for COVID-19 patients stable during the pandemic.
In China, Fresenius Kabi was able to bring manufacturing back up to the normal level. Despite some restrictions due to the COVID-19 pandemic and quarantine measures, it has not experienced any interruption in production. This means Fresenius Kabi is still in a position to provide the public with important pharmaceutical and medical products.
Our Chief Executive Officer, Stephan Sturm, thanks the employees for their exceptional dedication in this crisis: “You are all doing extraordinary things: At this very difficult time you are still there for our patients, and sometimes even seem to do the impossible. I can only express, once again, my most sincere thanks. You are Fresenius!”